Product Name

  • Name

    Moclobemide

  • EINECS
  • CAS No. 71320-77-9
  • Article Data57
  • CAS DataBase
  • Density 1.206 g/cm3
  • Solubility soluble in water
  • Melting Point 137 °C
  • Formula C13H17ClN2O2
  • Boiling Point 447.7 °C at 760 mmHg
  • Molecular Weight 268.743
  • Flash Point 224.6 °C
  • Transport Information
  • Appearance White to off-white solid
  • Safety 26-39-45-36/37/39-22
  • Risk Codes 22-37/38-41-26/27/28
  • Molecular Structure Molecular Structure of 71320-77-9 (Moclobemide)
  • Hazard Symbols HarmfulXn, VeryT+
  • Synonyms 4-Chloro-N-(2-morpholin-4-ylethyl)benzamide;4-Chloro-N-(2-morpholinoethyl)benzamide;Auromid;Aurorix;Manerix;Moclaime;Moclobemide;Ro 11-1163;Ro 11-1163/000;p-Chloro-N-(2-morpholinoethyl)-benzamide;
  • PSA 41.57000
  • LogP 1.73080

Synthetic route

4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

para-chlorobenzoic acid
74-11-3

para-chlorobenzoic acid

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With tetramethylorthosilicate In toluene at 110℃; for 1h; Inert atmosphere;100%
With zirconocene dichloride In toluene at 110℃; for 24h; Inert atmosphere; sealed tube;86%
With [((CH3)5Cp)2Zr(H2O)2OSO2C8F17]+[OSO2C8F17]-*THF In tetrahydrofuran at 100℃; for 12h; Catalytic behavior; Reagent/catalyst; Temperature;85%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

1-Chloro-4-iodobenzene
637-87-6

1-Chloro-4-iodobenzene

carbon monoxide
201230-82-2

carbon monoxide

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With triethylamine; triphenylphosphine; bis(dibenzylideneacetone)-palladium(0) In 1,4-dioxane at 80℃; for 18h; Glovebox; Sealed tube; Inert atmosphere;99%
With 1,4-diaza-bicyclo[2.2.2]octane; 9-{[5-(diphenylphosphanyl)-9,9-dimethyl-9H-xanthen-4-yl]diphenyl-λ4-phosphanyl}-O-methanesulfonyl-8-methyl-8λ4-aza-9-palladatricyclo[8.4.0.02,7]tetradeca-1(14),2,4,6,10,12-hexaene-9,9-bis(ylium)-10-uid-9-olate In tetrahydrofuran at 80℃; for 16h; Sealed tube;98%
With potassium carbonate In toluene at 120℃; under 1034.32 Torr; for 24h;94%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

1-Chloro-4-iodobenzene
637-87-6

1-Chloro-4-iodobenzene

chloroform
67-66-3

chloroform

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With cesiumhydroxide monohydrate; palladium diacetate; bis[2-(diphenylphosphino)phenyl] ether In toluene at 80℃; for 24h; Glovebox; Inert atmosphere; Sealed tube;99%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

1-((N,4-dimethylphenyl)sulfonamido)vinyl 4-chlorobenzoate

1-((N,4-dimethylphenyl)sulfonamido)vinyl 4-chlorobenzoate

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
In dichloromethane at 20℃; for 5h;98%
In dichloromethane at 25℃; for 5h;57 mg
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

C17H16ClNO3S2

C17H16ClNO3S2

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
In dichloromethane at 20℃; for 0.5h;98%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

bromochlorobenzene
106-39-8

bromochlorobenzene

carbon monoxide
201230-82-2

carbon monoxide

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With potassium carbonate; bis[2-(diphenylphosphino)phenyl] ether In toluene at 105℃; under 3000.3 Torr; for 12h;96%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

4-chloro-benzoyl chloride
122-01-0

4-chloro-benzoyl chloride

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With triethylamine at 0 - 20℃; for 13h;95%
With pyridine71%
With triethylamine In dichloromethane at 20℃; for 17h; Inert atmosphere;41%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

4-chlorobenzaldehyde
104-88-1

4-chlorobenzaldehyde

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With 1,2,4-Triazole; Phenazin; 4-ethyl-1-methyl-4H-[1,2,4]-triazol-1-ium iodide; 1,8-diazabicyclo[5.4.0]undec-7-ene In tetrahydrofuran at 20℃; for 24h; Schlenk technique; Inert atmosphere;92%
With nickel(II) chloride hexahydrate; hydroxylamine hydrochloride; sodium hydroxide In para-xylene at 155℃; for 18h; Inert atmosphere;73%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

Methyl 4-chlorobenzoate
1126-46-1

Methyl 4-chlorobenzoate

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With lithium hexamethyldisilazane In tetrahydrofuran; toluene at 23℃; for 15h; Inert atmosphere; chemoselective reaction;90%
With zirconium(IV) oxide In diethylene glycol dimethyl ether at 160℃; under 3750.38 Torr; Flow reactor; Green chemistry;80%
In diethyl ether
With family VIII carboxylesterase EstCE1 In dimethyl sulfoxide at 25℃; for 42h; Enzymatic reaction;
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

4-chlorobenzamide
619-56-7

4-chlorobenzamide

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With niobium(V) oxide In neat (no solvent) at 160℃; Sealed tube; Inert atmosphere;90%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

4-chlorobenzenecarbothioic acid
31143-03-0

4-chlorobenzenecarbothioic acid

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With 10-methyl-9-(2,4,6-trimethylphenyl) acridinium tetrafluoroborate In acetonitrile at 20℃; for 5h; Irradiation;89%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

4-nitrophenyl 4-chlorobenzoate
6264-29-5

4-nitrophenyl 4-chlorobenzoate

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
Stage #1: 4-nitrophenyl 4-chlorobenzoate With 1,3-dimethylimidazolim iodide; 1,8-diazabicyclo[5.4.0]undec-7-ene In tetrahydrofuran for 0.333333h; Schlenk technique;
Stage #2: 4-(2-AMINOETHYL)MORPHOLINE In tetrahydrofuran at 20℃; for 0.5h;
85%
With sodium hydroxide In tetrahydrofuran; dichloromethane; water
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

4-chloro-N-methyl-N-phenyl-benzamide
1517-46-0

4-chloro-N-methyl-N-phenyl-benzamide

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With lithium hexamethyldisilazane In tetrahydrofuran; toluene at 23℃; for 15h; Inert atmosphere; chemoselective reaction;81%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

1,3-dioxoisoindolin-2-yl 4-chlorobenzoate
63591-89-9

1,3-dioxoisoindolin-2-yl 4-chlorobenzoate

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
In acetonitrile for 2h;80%
In acetonitrile at 20℃; for 0.25h; Sealed tube;
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

4-Cyanochlorobenzene
623-03-0

4-Cyanochlorobenzene

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With Iron(III) nitrate nonahydrate at 125℃; for 24h; Sealed tube; Inert atmosphere;73%
With Iron(III) nitrate nonahydrate at 125℃; for 24h; Neat (no solvent); Sealed tube;54%
para-chlorotoluene
106-43-4

para-chlorotoluene

C6H13ClN2O

C6H13ClN2O

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With tert.-butylhydroperoxide; copper diacetate; tetra-(n-butyl)ammonium iodide at 80℃; Green chemistry;69%
bromochlorobenzene
106-39-8

bromochlorobenzene

diethyl-2,6-dimethyl-4-((2-morpholinoethyl)carbamoyl)-1,4-dihydropyridine-3,5-dicarboxylate

diethyl-2,6-dimethyl-4-((2-morpholinoethyl)carbamoyl)-1,4-dihydropyridine-3,5-dicarboxylate

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With (1,2-dimethoxyethane)dichloronickel(II); 4,4'-Dimethoxy-2,2'-bipyridin; (4s,6s)-2,4,5,6-tetra(9H-carbazol-9-yl)isophthalonitrile; sodium carbonate In tetrahydrofuran at 20℃; for 16h; Schlenk technique; Inert atmosphere; Sealed tube; Irradiation;67%
N-(2-bromoethyl)morpholine
89583-07-3

N-(2-bromoethyl)morpholine

4-chlorobenzamide
619-56-7

4-chlorobenzamide

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With potassium carbonate In dimethyl sulfoxide at 110℃; for 24h;62%
morpholine
110-91-8

morpholine

4-chloro-N-(2-hydroxyethyl)-benzamide
7400-54-6

4-chloro-N-(2-hydroxyethyl)-benzamide

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
Stage #1: 4-chloro-N-(2-hydroxyethyl)-benzamide With dmap; methanesulfonyl chloride; triethylamine; sodium chloride In dichloromethane at 20℃; for 24h;
Stage #2: morpholine at 100℃; for 2h;
49%
Stage #1: 4-chloro-N-(2-hydroxyethyl)-benzamide With dmap; triethylamine; sodium chloride In dichloromethane at 20℃; for 16h;
Stage #2: morpholine at 100℃; for 2h;
morpholine
110-91-8

morpholine

4-chloro-N-(2-chloroethyl)benzamide
51847-02-0

4-chloro-N-(2-chloroethyl)benzamide

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With ammonia In methanol at 100℃; for 2h;42%
With ammonia In ethanol; chloroform; water
Stage #1: morpholine; 4-chloro-N-(2-chloroethyl)benzamide at 100℃; for 2h;
Stage #2: With ammonium hydroxide at 20℃;
56.6 mg
1-(4-chlorophenyl)-2-(methylsulfonyl)diazene
56075-36-6

1-(4-chlorophenyl)-2-(methylsulfonyl)diazene

2-morpholinoethyl isonitrile
78375-48-1

2-morpholinoethyl isonitrile

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With sodium hydrogencarbonate In water; acetonitrile for 24h; Irradiation;40%
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

4-chlorobenzaldehyde
104-88-1

4-chlorobenzaldehyde

A

4-{2-[(p-chlorobenzylidene)-amino]-ethyl}-morpholine

4-{2-[(p-chlorobenzylidene)-amino]-ethyl}-morpholine

B

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
In water; benzene
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

para-chlorobenzoic acid
74-11-3

para-chlorobenzoic acid

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With triethylamine In dichloromethane; water; acetone
morpholine
110-91-8

morpholine

1-(4-chlorobenzoyl)aziridine
19117-21-6

1-(4-chlorobenzoyl)aziridine

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
In toluene
4-(2-AMINOETHYL)MORPHOLINE
2038-03-1

4-(2-AMINOETHYL)MORPHOLINE

1-(4-chlorobenzoyl)pyrrolidine-2,5-dione
6343-28-8

1-(4-chlorobenzoyl)pyrrolidine-2,5-dione

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
In 1,4-dioxane; ice-water
ethyloxirane
106-88-7

ethyloxirane

p-chloro-N-(2-morpholinoethyl)-thiobenzamide hydrochloride
32417-60-0

p-chloro-N-(2-morpholinoethyl)-thiobenzamide hydrochloride

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
In methanol
p-chloro-N-(2-morpholinoethyl)-thiobenzamide hydrochloride
32417-60-0

p-chloro-N-(2-morpholinoethyl)-thiobenzamide hydrochloride

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With lead(IV) tetraacetate In ethanol; chloroform; water
(4-chloro-benzylidene)-(2-morpholin-4-yl-ethyl)-amine oxide
31856-94-7

(4-chloro-benzylidene)-(2-morpholin-4-yl-ethyl)-amine oxide

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
With sodium hydroxide; acetic anhydride In ice-water; ethanol; chloroform; acetic acid
para-Chlorobenzyl alcohol
873-76-7

para-Chlorobenzyl alcohol

moclobemide
71320-77-9

moclobemide

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: iron(II) chloride tetrahydrate; calcium carbonate; tert.-butylhydroperoxide / acetonitrile; water / 4 h / 80 °C / Sealed tube
2.1: sodium tetrahydroborate / tetrahydrofuran / 0.25 h / 65 °C
2.2: 0.25 h / 65 °C
3.1: sodium chloride; methanesulfonyl chloride; triethylamine; dmap / dichloromethane
4.1: ammonia / methanol / 2 h / 100 °C
View Scheme
Multi-step reaction with 2 steps
1.1: iron(II) chloride tetrahydrate; calcium carbonate; tert.-butylhydroperoxide / acetonitrile / 4 h / 80 °C
2.1: 2 h / 100 °C
2.2: 20 °C
View Scheme
Multi-step reaction with 3 steps
1.1: iron(II) chloride tetrahydrate; calcium carbonate; tert.-butylhydroperoxide / acetonitrile / 4 h / 80 °C
2.1: triethylamine; dmap; sodium chloride; methanesulfonyl chloride / dichloromethane
3.1: 2 h / 100 °C
3.2: 20 °C
View Scheme
moclobemide
71320-77-9

moclobemide

bis(pinacol)diborane
73183-34-3

bis(pinacol)diborane

(S)-4-chloro-N-(2-morpholino-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)benzamide

(S)-4-chloro-N-(2-morpholino-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)benzamide

Conditions
ConditionsYield
With 2,6-dimethylpyridine; [Rh(OH)(cod)]2; (11bR)-4-(((R)-2'-((triisopropylsilyl)oxy)-[1,1'-binaphthalen]-2-yl)oxy)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine In acetonitrile at 60℃; for 15h; Inert atmosphere; Sealed tube; enantioselective reaction;79%
potassium hydrogenfluoride
1279123-63-5

potassium hydrogenfluoride

moclobemide
71320-77-9

moclobemide

bis(pinacol)diborane
73183-34-3

bis(pinacol)diborane

N-(2-morpholinoethyl)-4-(trifluoro-λ4-boraneyl)benzamide potassium salt

N-(2-morpholinoethyl)-4-(trifluoro-λ4-boraneyl)benzamide potassium salt

Conditions
ConditionsYield
Stage #1: moclobemide; bis(pinacol)diborane With 10H-phenothiazine; caesium carbonate In acetonitrile for 48h; Irradiation; Sealed tube; Inert atmosphere;
Stage #2: With hydrogenchloride; dihydroxy-methyl-borane In water; acetone
Stage #3: potassium hydrogenfluoride Further stages;
66%
4-Methoxybenzenethiol
696-63-9

4-Methoxybenzenethiol

moclobemide
71320-77-9

moclobemide

4-((4-methoxyphenyl)thio)-N-(2-morpholinoethyl)benzamide

4-((4-methoxyphenyl)thio)-N-(2-morpholinoethyl)benzamide

Conditions
ConditionsYield
With C24H22N6Ni; sodium t-butanolate In N,N-dimethyl-formamide; acetonitrile at 20℃; for 24h; Inert atmosphere; Schlenk technique;61%
With caesium carbonate In dimethyl sulfoxide at 25℃; for 26h; Irradiation; Inert atmosphere;50%
With caesium carbonate In dimethyl sulfoxide at 25℃; for 26h; Inert atmosphere; UV-irradiation;50%
moclobemide
71320-77-9

moclobemide

Ro 12-5637

Ro 12-5637

Conditions
ConditionsYield
With human flavin monooxygenase-3 recombinant; NAD; sodium citrate; magnesium chloride In methanol at 27℃; for 24h; pH=8.5; aq. phosphate buffer; Enzymatic reaction;55%
With sodium phosphate buffer; human liver microsomes; NADPH-generating system at 37℃; for 1h; pH=7.4; Enzyme kinetics; Further Variations:; pH-values; time;
moclobemide
71320-77-9

moclobemide

C13H18ClN3O2

C13H18ClN3O2

Conditions
ConditionsYield
With ferrous(II) sulfate heptahydrate; trifluorormethanesulfonic acid; CH5NO3S*CHF3O3S at 60℃; for 2h;55%
1-bromo-2-triethylsilylacetylene
38177-63-8

1-bromo-2-triethylsilylacetylene

moclobemide
71320-77-9

moclobemide

4-chloro-N-(2-morpholinoethyl)-2-[(triethylsilyl)ethynyl]benzamide

4-chloro-N-(2-morpholinoethyl)-2-[(triethylsilyl)ethynyl]benzamide

Conditions
ConditionsYield
With chromium chloride; trimethylaluminum In 1,2-dimethoxyethane; toluene at 70℃; for 24h; Schlenk technique;47%
moclobemide
71320-77-9

moclobemide

1-azido-6-bromohexane
235095-05-3

1-azido-6-bromohexane

C19H28ClN5O2

C19H28ClN5O2

Conditions
ConditionsYield
Stage #1: moclobemide With sodium hydride In N,N-dimethyl-formamide at 0 - 20℃; for 0.333333h; Inert atmosphere;
Stage #2: 1-azido-6-bromohexane In N,N-dimethyl-formamide at 20℃; for 2h; Inert atmosphere;
32%

Moclobemide History

Although clinical trials with the medicine began in 1977, it is not approved for use in the United States. It is produced by affiliates of the Hoffmann-La Roche pharmaceutical company.

Moclobemide Specification

The Moclobemide is an organic compound with the formula C13H17ClN2O2. The IUPAC name of this chemical is 4-chloro-N-(2-morpholin-4-ylethyl)benzamide. With the CAS registry number 71320-77-9, it is also named as Benzamide, 4-Chloro-N-(2-(4-morpholinyl)ethyl)-. The product's categories are Active Pharmaceutical Ingredients; All Inhibitors; Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals; API's; Monoamine Oxidase. Besides, it is a white to off-white solid.

Physical properties about Moclobemide are: (1)ACD/LogP: 0.84; (2)ACD/LogD (pH 5.5): -0.6; (3)ACD/LogD (pH 7.4): 0.71; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1.91; (6)ACD/KOC (pH 5.5): 2.47; (7)ACD/KOC (pH 7.4): 50.95; (8)#H bond acceptors: 4; (9)#H bond donors: 1; (10)#Freely Rotating Bonds: 4; (11)Polar Surface Area: 32.78 Å2; (12)Index of Refraction: 1.55; (13)Molar Refractivity: 71.03 cm3; (14)Molar Volume: 222.8 cm3; (15)Polarizability: 28.16×10-24cm3; (16)Surface Tension: 43.3 dyne/cm; (17)Density: 1.206 g/cm3; (18)Flash Point: 224.6 °C; (19)Enthalpy of Vaporization: 70.61 kJ/mol; (20)Boiling Point: 447.7 °C at 760 mmHg; (21)Vapour Pressure: 3.29E-08 mmHg at 25°C.

Preparation: this chemical can be prepared by 4-chloro-benzoyl chloride. This reaction will need reagent pyridine. The yield is about 71%.



Uses of Moclobemide: in efficacy studies for the treatment of major depressive disorder, moclobemide has been found to be significantly more effective than placebo, as effective as the tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), and somewhat less effective than the older, irreversible MAOIs phenelzine and tranylcypromine. In terms of tolerability, however, moclobemide was found to be comparable to the SSRIs and better tolerated than the TCAs and older MAOIs. In addition, moclobemide is occasionally used recreationaly when mixed with the prototypical psychedelic dimethyltryptamine (DMT). Orally ingested DMT is inactive, as it is rapidly metabolized by gut monoamine oxidase enzymes, hence these enzymes must be temporarily inhibited in order for DMT to pass into the bloodstream intact. The combination of DMT-containing plants and the plant-based MAO-inhibiting harmala alkaloids (harmine, harmaline) is referred to as Ayahuasca, a psychedelic brew used by several native tribes of South America in traditional spiritual ceremonies. Moclobemide serves a similar purpose to the harmala alkaloids and has been used in modern synthetic recapitulations of the Ayahuasca ritual and such a mixture, in which a synthetic MAOI is used in conjunction with DMT is commonly being referred to as "Pharmahuasca".

When you are using this chemical, please be cautious about it as the following:
It is harmful if swallowed and very toxic by inhalation, in contact with skin and if swallowed. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Besides, this chemical is irritating to respiratory system and skin and risk of serious damage to eyes. When you are using it, wear suitable gloves and eye/face protection and do not breathe dust. In case of accident or if you feel unwell seek medical advice immediately (show the label where possible).

You can still convert the following datas into molecular structure:
(1)SMILES: Clc1ccc(cc1)C(=O)NCCN2CCOCC2
(2)InChI: InChI=1/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
(3)InChIKey: YHXISWVBGDMDLQ-UHFFFAOYAU
(4)Std. InChI: InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
(5)Std. InChIKey: YHXISWVBGDMDLQ-UHFFFAOYSA-N

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo oral 45mg/kg/2W-I (45mg/kg) BEHAVIORAL: CHANGE IN REM SLEEP (HUMAN)

BEHAVIORAL: MUSCLE WEAKNESS
Human Psychopharmacology. Vol. 13, Pg. 377, 1998.
mouse LD oral > 1gm/kg (1000mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Journal of Pharmacology and Experimental Therapeutics. Vol. 284, Pg. 983, 1998.
mouse LD50 intraperitoneal 591mg/kg (591mg/kg)   European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 31, Pg. 909, 1996.
rat LD50 oral 707mg/kg (707mg/kg)   United States Patent Document. Vol. #4210754,
women TDLo oral 5mg/kg/5W-I (5mg/kg) SKIN AND APPENDAGES (SKIN): HAIR: OTHER Human Psychopharmacology. Vol. 12, Pg. 81, 1997.
women TDLo oral 19mg/kg (19mg/kg) BEHAVIORAL: SLEEP

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

GASTROINTESTINAL: NAUSEA OR VOMITING
Journal of Clinical Psychiatry. Vol. 47, Pg. 438, 1986.
women TDLo oral 66mg/kg/11D-I (66mg/kg) VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION Lancet. Vol. 346, Pg. 1032, 1995.
women TDLo oral 12600mg/kg/14 (12600mg/kg) BLOOD: THROMBOCYTOPENIA

BLOOD: LEUKEMIA

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Lancet. Vol. 347, Pg. 1329, 1996.

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View